Pfizer Inc. announced today enrollment of the first patient in a multicenter Phase II clinical trial of the investigational compound PF-06252616 in boys with Duchenne muscular dystrophy (DMD), a genetic disorder characterized by progressive muscle degeneration and weakness. PF-06252616 is an experimental, infused, anti-myostatin monoclonal antibody. Myostatin is a naturally…

Today Parent Project Muscular Dystrophy (PPMD) named Massachusetts General Hospital (MGH) our sixth Certified Duchenne Care Center, recognizing the Hospital’s dedication to improving care for people living with Duchenne.

Earlier this year,…

I am Anessa Fehsenfeld, PPMD’s Board Chairman. More importantly, though, my husband Scott and I are the parents of three beautiful kids Bekah (18), Tyler (15), and Hudson (11). Tyler has Duchenne. Almost immediately after his diagnosis, I found PPMD, and they’ve been a godsend. As the mother of a teen with Duchenne, I can’t begin to tell you how much I’ve appreciated PPMD’s ability to look at the whole disease and help our family navigate his diagnosis at every age, every…

Parent Project Muscular Dystrophy (PPMD) announced today a collaboration with Catabasis Pharmaceuticals, Inc. (Catabasis) to assist in a Phase 2 clinical trial of its CAT-1004 product candidate for the treatment of patients with Duchenne. As part of this collaboration, PPMD will provide funding to support participant…

Parent Project Muscular Dystrophy (PPMD) has awarded Akashi Therapeutics, Inc. (Akashi) a $500,000 grant to fund clinical trials to test the safety and efficacy of an investigational new drug known as HT-100 (delayed-release…